Indoleamine 2,3-dioxygenase (IDO), which catalyzes the breakdown of the essential amino acid tryptophan into kynurenine, is understood to have a key role in cancer immunotherapy because of its role in enabling cancers to evade the immune system. This evidence concerns the gene IDO1 and cancer.